Table 3.
Odds ratios (95% CIs) for the association between change in oxylipin concentrations and follow-up adenoma endpoints, overall and stratified by treatment group (n = 256).
| Oxylipin | Overall a n = 256 (OR, 95% CI) d |
Selenium b n = 125 (OR, 95% CI) |
Placebo c n = 131 (OR, 95% CI) |
|||
|---|---|---|---|---|---|---|
| Category of Metabolite Concentration | Non-Advanced | Advanced | Non-Advanced | Advanced | Non-Advanced | Advanced |
| PGE2 (pg/mL) | ||||||
| 1 (−2.8 to −0.0002) | Ref | Ref | Ref | Ref | Ref | Ref |
| 2 (−0.0003 to 14.2) | 1.41 (0.85–2.00) | 1.46 (0.54–3.97) | 1.54 (0.67–3.49) | 0.64 (0.20–2.04) | 1.24 (0.55–2.80) | 0.72 (0.22–2.28) |
| 20-HETE (pg/mL) | ||||||
| 1 (−0.004 to 0.00) | Ref | Ref | Ref | Ref | Ref | Ref |
| 2 (0.01 to 11.9) | 0.98 (0.54–1.77) | 1.54 (0.69–3.45) | 1.01 (0.43–2.36) | 1.95 (0.61–6.25) | 0.95 (0.40–2.19) | 1.16 (0.36–2.49) |
| 12-HETE (pg/mL) | ||||||
| 1 (−57.1 to 0.0) | Ref | Ref | Ref | Ref | Ref | Ref |
| 2 (0.01 to 80.3) | 1.40 (0.74–2.63) | 1.30 (0.45–3.13) | 1.09 (0.46–2.58) | 0.83 (0.25–2.81) | 1.55 (0.58–4.14) | 2.29 (0.59–8.90) |
| 5-HETE (pg/mL) | ||||||
| 1 (−300.8 to 0.00) | Ref | Ref | Ref | Ref | Ref | Ref |
| 2 (0.01 to 2583.5) | 1.21 (0.66–2.21) | 1.33 (0.58–3.03) | 0.97 (0.40–2.37) | 1.67 (0.53–5.3) | 1.62 (0.32–3.67) | 1.09 (0.32–3.69) |
a Includes 126 individuals who had an advanced lesion and 130 who had a non-advanced adenoma at baseline. b Includes 64 individuals who had an advanced lesion and 61 participants who had a non-advanced adenoma at baseline. c Includes 62 individuals who had an advanced lesion and 69 participants who had a non-advanced adenoma at baseline. d Logistic regression models adjusted for age, sex, and NSAID use. Zero values transformed to LOQ/2. PGE2: prostaglandin E2; 20-HETE: 20-hydroxyeicosatetraenoic acid; 12-HETE: 12-hydroxyeicosatetraenoic acid; 5-HETE: 5-hydroxyeicosatetraenoic acid.